January 3, 2012
Antigen Accelerates Drug Development Pace
By Brandon Butler
Positive results from initial clinical trials have accelerated Worcester-based biotech firm Antigen Express's plans to commercialize its therapy, the company announced.
AE37 is a cancer vaccine aimed at preventing recurrence in patients who have been treated for the condition in the past. Clinical trials so far have focused on patients with breast and prostate cancer.
Initial results of the company's Phase 2b clinical trial produced such positive results that the company has moved up its planned meeting with the U.S. Food & Drug Administration to plan a Phase 3 trial. Antigen now hopes that meeting will take place by the end of March.
Antigen Express is a wholly-owned subsidiary of Toronto-based Generex Biotechnology.
WBJ Web Partners
Most Recent
Most Recent
0 Comments